CompletedPhase 1NCT00501748
Safety and Tolerability of Rituximab in Neuromyelitis Optica
Studying Neuromyelitis optica spectrum disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- University of California, San Francisco
- Principal Investigator
- Bruce Cree, MD, PhDMS Center , UCSF
- Intervention
- Rituximab(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 12-86 years · All sexes
- Timeline
- 2004 – 2010
Study locations (2)
- UCSF MS Center , 350 Parnassus Ave , suite #908, San Francisco, California, United States
- The Neurological Institute of New York MS Center, Columbia University Medical Center 710 West 168th Street,, New York, United States
Collaborators
Genentech, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00501748 on ClinicalTrials.govOther trials for Neuromyelitis optica spectrum disorder
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07377305Efficacy and Safety of Transcranial Temporal Interference Stimulation (tTIS) for Neuropathic Pain in Neuromyelitis Optica Spectrum Disorder (NMOSD)Tang-Du Hospital
- RECRUITINGNCT05891379Inebilizumab in Acute Neuromyelitis Optica Spectrum DisordersXuanwu Hospital, Beijing
- RECRUITINGNCT05004493Biorepository and Registry for Plasma Exchange PatientsCharles M Knudson
- RECRUITINGNCT04106830Clinical and Imaging Cohort of Neuroinflammation Diseases in China (CLUE)Beijing Tiantan Hospital
- ACTIVE NOT RECRUITINGNCT01623076The Longitudinal CONQUER Study of Rare Neuroimmunologic DisordersUniversity of Texas Southwestern Medical Center